Ophthalmology's diverse pipeline could rejuvenate previously stagnant therapy area; Report

The ophthalmology market has experienced relatively little advancement in recent years and, with large unmet needs remaining in this area, there are strong opportunities for more products to enter the treatment space, new research indicates

According to business intelligence provider GBI Research’s latest report, scientific advancements in this therapy area – which includes glaucoma, age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy and dry eye syndrome – have revealed a broad range of novel potential molecular targets in recent decades, enabling progress in a previously stagnant field. This is reflected by the high number of products in development, with 782 products currently in the ophthalmology therapy pipeline.

Dominic Trewartha, managing analyst for GBI Research, explains: “The ophthalmology pipeline contains a diverse range of molecular targets and no single target dominates by any clear margin. However, products acting on components of the immune system – largely cytokine and cytokine receptors – and its regulatory signalling pathways make up the largest segment, followed by angiogenesis inhibitors.”